Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 4Recruiting 3Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 23Kidney Neoplasms 7Carcinoma, Hepatocellular 7Osteosarcoma 5Sarcoma, Ewing 4Neoplasm Metastasis 4Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

Doxorubicin 15pembrolizumab 12Cyclophosphamide 9Surgical Procedures, Operative 8Gemcitabine 8Blood Specimen Collection 8Ifosfamide 7Surveys and Questionnaires 6Nivolumab 6Trabectedin 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Drug Therapy 5fludarabine 4Temozolomide 4Specimen Handling 4Radiation Dose Hypofractionation 4Biopsy 4selinexor 3pazopanib 3liposomal doxorubicin 3cabozantinib 3atezolizumab 3anlotinib 3Radiation 3Observation 3Docetaxel 3Dacarbazine 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Sarcoma × cabozantinib × Clear all
NCT06156410 2025-11-14

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Children's Hospital of Philadelphia

Phase 1 Recruiting
30 enrolled
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT05182164 2025-10-07

PEMBROCABOSARC

Institut Bergonié

Phase 2 Recruiting
119 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

Phase 2 Recruiting
86 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡